Pharmacokinetics News and Research RSS Feed - Pharmacokinetics News and Research

The term pharmacokinetics is derived from the ancient Greek words “pharmakon” and “kinetikos”, meaning “drug” and “putting in motion” respectively. It is one of the main branches of pharmacology, and refers to the way that the body reacts on and affects a pharmaceutical substance in the body.
Further Reading
Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix announces positive results from Phase 1 study of novel dry powder formulation in COPD patients

Pulmatrix, Inc., today announced positive topline data from a Phase 1 pilot pharmacokinetic bioavailability trial of PUR0200. PUR0200 is a novel dry powder formulation of a currently marketed once daily bronchodilator, formulated in the company's proprietary iSPERSETM dry powder delivery technology. [More]
Minoryx Therapeutics initiates phase 1 clinical trial of MIN-102

Minoryx Therapeutics initiates phase 1 clinical trial of MIN-102

Minoryx Therapeutics, a drug development company specialized in the discovery and development of new drugs for orphan diseases, today announces the initiation of its first-in-man Phase 1 clinical trial for its lead compound MIN-102. [More]
Article reviews impact of adding pyridine based antitumor compounds at colchicine site

Article reviews impact of adding pyridine based antitumor compounds at colchicine site

Tubulin inhibitors are amongst the most successful anti-cancer, anti-parasitic and herbicidal agents. Their vascular disrupting activity has recently attracted research focus as it elicits anti-cancer effects at doses well below that of other toxic agents. [More]
Inhalable ibuprofen holds potential to treat cystic fibrosis

Inhalable ibuprofen holds potential to treat cystic fibrosis

Ibuprofen: You can buy it at any drug store, and it will help with that stabbing headache or sprained ankle. One of the ways it does so is by reducing inflammation, and it is this property that may also help patients with cystic fibrosis. [More]
Study examines how gender and FH may affect alcohol use in adolescents

Study examines how gender and FH may affect alcohol use in adolescents

Gender and a family history of alcoholism (FH) are two genetically determined factors known to affect someone's risk for developing alcohol-use disorders (AUDs). Adolescence is also a critical period for the development of AUDs; drinking habits can be unstable and environmental factors such as peer pressure may be substantial. [More]
Novel imaging technique may assist surgeons to improve visualization of ovarian tumors during surgery

Novel imaging technique may assist surgeons to improve visualization of ovarian tumors during surgery

A newly devised tumor-specific fluorescent agent and imaging system guided surgeons in real time to remove additional tumors in ovarian cancer patients that were not visible without fluorescence or could not be felt during surgery. [More]
Topical delivery of AVR drug combination can provide complete protection against HIV

Topical delivery of AVR drug combination can provide complete protection against HIV

Researchers are edging ever closer to discovering the perfect combination of drugs and drug delivery system that will stop the sexual transmission of HIV. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Scientists provide overview of most promising compounds to combat prostate cancer

Scientists provide overview of most promising compounds to combat prostate cancer

Scientists from MIPT (Moscow Institute of Physics and Technology), MSU (Moscow State University), and National University of Science and Technology “MISIS” provided an overview of the most promising compounds which can be used as medications for prostate cancer. [More]
BioAgilytix announces acquisition of IPM Biotech

BioAgilytix announces acquisition of IPM Biotech

BioAgilytix, a leading provider of contract bioanalytical testing services specializing in large molecule bioanalysis, has announced the acquisition of IPM Biotech, a German-based bioanalytical contract research laboratory renowned for its expertise in large molecule bioanalysis, particularly in the area of immunogenicity. [More]
Biomarkers may provide novel approaches to monitoring immunosuppressive therapy in organ transplant patients

Biomarkers may provide novel approaches to monitoring immunosuppressive therapy in organ transplant patients

Recently discovered biomarkers may provide valuable new approaches to monitoring immunosuppressive drug therapy in organ transplant recipients--with the potential for individualized therapy to reduce organ rejection and minimize side effects, according to a special article in the April issue of Therapeutic Drug Monitoring, official journal of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. [More]
Rutgers' new drug candidate may help fight malaria

Rutgers' new drug candidate may help fight malaria

Malaria killed about 440,000 people - mostly young children - last year, but a new drug candidate discovered at Rutgers may help fight the long-dreaded disease. [More]
Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor begins XmAb5871 Phase 2 trials in patients with IgG4-RD and Systemic Lupus Erythematosus

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced dosing the first patient in a Phase 2 trial of XmAb5871 in patients with IgG4-Related Disease (IgG4-RD). [More]
New drug shows promise against Huntington's disease

New drug shows promise against Huntington's disease

A drug that would be the first to target the cause of Huntington's disease (HD) is effective and safe when tested in mice and monkeys, according to data released today that will be presented at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016. [More]
Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus reports net loss of $7.2 million for fourth quarter 2015

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today reported financial results for the fourth quarter and full-year ended December 31, 2015 and provided a summary of recent corporate highlights. [More]
AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI's net revenues increase $126.4M to 46% in fourth quarter 2015

AMRI today reported financial and operating results for the fourth quarter and full year ended December 31, 2015 and provided an outlook for 2016. [More]
Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan's sNDA for TEFLARO (ceftaroline fosamil) accepted by FDA

Allergan plc today announced the U.S. Food and Drug Administration has accepted for filing the company's supplemental New Drug Application (sNDA) for TEFLARO (ceftaroline fosamil). [More]
Ambrisentan avoids sildenafil drug interaction in PAH patients

Ambrisentan avoids sildenafil drug interaction in PAH patients

Sildenafil may be better given to pulmonary arterial hypertension patients in combination with ambrisentan than with bosentan, study findings suggest. [More]
Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

Molecular imaging and radiochemistry: the importance of instrumentation. An interview with Professor Björn Wängler

I’m Björn Wängler, Professor for Molecular Imaging and Radiochemistry at the medical faculty Mannheim of Heidelberg University. I’m a radiopharmaceutical chemist by background and completed my PhD in 2004 at the University of Mainz. [More]
MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax receives FDA authorization to initiate 89Zr-HuMab-5B1 Phase I trial in pancreatic cancer patients

MabVax Therapeutics Holdings, Inc., a clinical-stage oncology drug-development company, announces receipt of notice from the U.S. Food and Drug Administration authorizing initiation of a Phase I clinical trial with 89Zr-HuMab-5B1 as a new generation PET scan cancer imaging agent in patients with pancreatic cancer. [More]
Advertisement